MissionIRNewsBreaks – Earth Science Tech, Inc. (ETST) Finalizes Plans for Human Trial of CBD-based Formula Targeting Opioid Addiction

Earth Science Tech, Inc. (OTC: ETST) this morning reported that it has finalized preparations for its nine-month human trial to evaluate the effectiveness of a blend of broad-spectrum cannabinoid industrial hemp oil and essential mineral element. The trial seeks to develop a CBD formulation for the treatment of opioid addicts, relieving withdrawal symptoms, and averting fatal overdoses. ETST aims to increase the potency of its formulation by combining its full-spectrum cannabinoids industrial hemp oil with essential minerals. The trial is scheduled to be completed in 2019 and it will be supervised by ETST chief learning officer Gabriel Aviles and CEO Dr. Michel Aube. Per the update, ETST is prepared to manufacture and introduce new products in the market to combat the current scourge of opioid deaths in America if the formulation proves successful. ETST is currently collaborating with CGMP laboratory to mix the anti-opioid formula for the human trials, and it is in talk with rehabilitation centers that are interested in participating in the project.

To view the full press release, visit http://ibn.fm/cQtrb

About Earth Science Tech, Inc.

Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil. To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRA: 6F6) (WKN: A2AKL8) Continues Riding Momentum in a Momentous Year

• Stock price increased by more than $3.00 in a two-month period


• Various acquisitions and partnerships in 2018


• Focused on incubating the new century’s technology giants

From numerous recent acquisitions to a stock price that has climbed dramatically in the past year, it’s an exciting time for blockchain-focused venture builder Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8).

Engaged in funding and empowering entrepreneurs to implement cutting-edge blockchain solutions, Victory Square is in the business of incubating a new generation of technology titans. The company’s diversified portfolio includes investment interests in the gaming, health care, artificial intelligence and virtual reality sectors, as well as others, and Victory Square’s portfolio companies are effectively disrupting a wide range of sectors across the global economy.

So far in 2018, Victory Square has announced various important acquisitions, including a 100 percent acquisition of established mobile games studio V2 Games Inc. (http://ibn.fm/PlGkn), a 31.35 percent acquisition of emerging payment processing company PayVida Solutions Inc. (http://ibn.fm/Viecy), and a 23.1 percent acquisition of emerging blockchain-focused fintech company Cassia Research Inc. (http://ibn.fm/AlbwZ). The company has further forged various exciting strategic partnerships this year.

Victory Square’s stock has enjoyed an impressive boost in a short amount of time, climbing from $0.298 in October 2017 to an impressive $3.32 by December 2017. As of February 27, the company’s price has remained well above $2.00 per share.

Victory Square operates on the idea that impactful companies are built upon experimentation of bold ideas, and entrepreneurs working with the company have invaluable access to Victory Square’s education programs, global mentor network, distribution partners, creative workspaces, operational support and other resources to help them scale on an international level.

The company’s impressive brag sheet includes assisting more than 1,000 entrepreneurs and more than 500 startups to date, helping these entities collectively raise over $100 million and create more than 1,000 jobs.

Victory Square recognizes blockchain as the new major technology and the next key platform for innovation, with the ability to revolutionize the interconnections and operations of business and social structures. Leveraging its extensive expertise and standout prowess in building companies, Victory Square is hard at work identifying, incubating, advising and investing in the industry’s very best blockchain entrepreneurs.

For more information, visit the company’s website at www.VictorySquare.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Completes Acquisition of ERS Holdings; Announces Private Placement of Convertible Debentures

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) this morning announced the successful completion of its acquisition of ERS Holdings, LLC (“ERS”). ERS, a privately-held California company, has developed a patented technology called Ready-To-Infuse-Cannabis (“RTIC”) which covers the transformation of cannabis oil into powder for infusion into various food and beverage products. In addition, ERS has filed several continuation patents that would permit cannabis powder to be combined with other health and wellness products such as natural sleep-aids, cold medications and vitamins. Ross Franklin, co-inventor of the patent, has been appointed as the Director of Research and Development of ERS and will continue to invent novel ways to infuse cannabis into foods and beverages. Additionally, Patrick J. Rolfes has been appointed as President of ERS Holdings. “With this acquisition, we have positioned Pivot to be at the forefront of this enormous new market. Closing this transaction will enable us to further engage interested parties to work with us on developing the full potential of these Patents. Pivot intends to monetize the Patents as quickly as possible and thus I am delighted that Patrick Rolfes and Ross Franklin have joined the Pivot team to accelerate the process,” Pivot Pharmaceuticals CEO Dr. Patrick Frankham stated in the news release. The company also announced a private placement offering of senior secured convertible debentures with a conversion price of $1.74 per common share for aggregate gross proceeds of C$5,000,000. The offering is expected to be completed on or about February 28, 2018, subject to the satisfaction of customary of conditions.

To view the full press release, visit http://ibn.fm/pvr9U

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot Pharmaceutical’s subsidiary, Pivot Green Stream Health Solutions Inc., will focus on improving the bioavailability of cannabinoid-based pharmaceuticals. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids that can receive a Health Canada Natural Health Product designation. For more information, visit www.PivotPharma.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters Agreement to Create Unique Analytical System Using Patented Pressure Cycling Technology

Pressure BioSciences (OTCQB: PBIO) recently entered a global co-marketing and distribution agreement with ISS, Inc. to create an advanced high pressure optical spectroscopy system utilizing PBIO’s patented pressure cycling technology (“PCT”). An article further discussing the agreement reads: “A leading developer and provider of innovative high pressure-based solutions to the global life sciences industry, Pressure BioSciences, Inc. (OTCQB: PBIO) has entered a two-year agreement with ISS, Inc., a prominent designer and manufacturer of advanced scientific instruments with more than 30 years of experience in the field. Under the agreement, the two companies will join their marketing and distribution efforts worldwide, as well as their own technologies to create an advanced high pressure optical spectroscopy system that’s expected to generate significant data that could be critical to the discovery and development of new biopharmaceutical diagnostics and drugs, according to a Pressure BioSciences press release issued on February 14, 2018 (http://ibn.fm/qMEmi).

To view the full article, visit http://ibn.fm/PfOg0

About Pressure BioSciences Inc.

Pressure BioSciences Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. PBI’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of PBI’s patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Earth Science Tech, Inc. (ETST) Focuses on Completing Key Projects in 2018

Science-based biotechnology company Earth Science Tech, Inc. (OTC: ETST) has set its sights on a momentous year in 2018 with many noteworthy tasks on the horizon. An article discussing the company reads: “Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://ibn.fm/H7rdz). The funds would be used to finance its planned projects in the new year and for general working capital (http://ibn.fm/Fzs5g), with share cancellation by company founders counteracting dilution. … ETST is also eyeing expansion into Canada in 2018, and it has appointed an attorney who will serve as consultant for ETST’s activities in that country, Avi Levi, Esq. (http://ibn.fm/rXqHj). He will help the company apply for licenses to import its CBD-rich hemp oil into Canada. It will then be exported to various countries as raw hemp oil or in individual ready-to-consume bottles, the company said.”

To view the full article, visit http://ibn.fm/FbbFY

About Earth Science Tech, Inc.

Earth Science Tech has among the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the superior supercritical CO2 liquid extraction, the company’s CBD Oil is 100% natural and organic. Earth Science Tech’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, validates the company’s position as a leading nutritional and dietary supplement brand for High Grade Hemp CBD Oil. For more information, visit the company’s website at www.EarthScienceTech.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html